HAI CHEN
Prescription History 1013237270
Psychiatry & Neurology - Epilepsy in New York, NY

NPI Status: Active since June 09, 2010

Contact Information

525 E 68TH ST DEPT OF NEUROLOGY
NEW YORK, NY
ZIP 10065
Phone: (212) 746-9259

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for HAI CHEN, an active Epilepsy specialist practicing in New York, NY. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 279 documented patient claims. Among these therapy options, the most frequently utilized medication is Levetiracetam, which accounts for 129 claims alone.

Medication Index


Clobazam

Generic Formulation: ClobazamSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NY State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills47.2
Peer Average Days Supply1,389
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.0% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,067.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$172.26

State Avg Cost Per Claim

$234.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.

Therapeutic Applications

This medication is used with other medications to help control seizures. It belongs to a class of medications called benzodiazepines, which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).

Divalproex Sodium

Generic Formulation: Divalproex SodiumSpecialty: Neurology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
NY State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills53.5
Peer Average Days Supply1,429
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.3% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $527.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.40

State Avg Cost Per Claim

$45.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Lacosamide

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 25
30-Day Fills 30.1
Days Supply 891
NY State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills37.1
Peer Average Days Supply1,034
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,973.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$318.93

State Avg Cost Per Claim

$291.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Lamotrigine

Generic Formulation: LamotrigineSpecialty: Neurology
Provider Metrics Summary
Total Claims 32
30-Day Fills 52.1
Days Supply 1,562
NY State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills63.0
Peer Average Days Supply1,843
Conservative Utilization

This provider writes prescriptions for this formulation 28.9% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,239.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.75

State Avg Cost Per Claim

$16.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 129
30-Day Fills 193.4
Days Supply 5,800
NY State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills70.3
Peer Average Days Supply1,936
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 152.9% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,178.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.39

State Avg Cost Per Claim

$37.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Oxcarbazepine

Generic Formulation: OxcarbazepineSpecialty: Neurology
Provider Metrics Summary
Total Claims 20
30-Day Fills 28.1
Days Supply 842
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills40.2
Peer Average Days Supply1,170
Conservative Utilization

This provider writes prescriptions for this formulation 35.5% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,276.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$63.84

State Avg Cost Per Claim

$65.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.

Therapeutic Applications

Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy).

Phenobarbital

Generic Formulation: PhenobarbitalSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
NY State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills29.2
Peer Average Days Supply852
Conservative Utilization

This provider writes prescriptions for this formulation 46.2% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $356.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.45

State Avg Cost Per Claim

$37.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

Therapeutic Applications

This medication is used alone or with other medications to control seizures. Controlling and reducing seizures lets you do more of your normal daily activities, reduces your risk of harm when you lose consciousness, and lessens your risk for a possibly life-threatening condition of frequent, repeated seizures. Phenobarbital belongs to a class of drugs known as barbiturate anticonvulsants/hypnotics. It works by controlling the abnormal electrical activity in the brain that occurs during a seizure. This medication is also used for a short time (usually no more than 2 weeks) to help calm you or help you sleep during periods of anxiety. It works by affecting certain parts of the brain to cause calming.

Zonisamide

Generic Formulation: ZonisamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 27
30-Day Fills 39.0
Days Supply 1,160
NY State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills45.0
Peer Average Days Supply1,304
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $932.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.54

State Avg Cost Per Claim

$40.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Therapeutic Applications

Zonisamide is used with other medications to prevent and control seizures (epilepsy). Zonisamide is a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It is unknown how zonisamide works to prevent seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like HAI CHEN provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Epilepsy ** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.